INDEX — InDex Pharmaceuticals Holding AB Share Price
0.000.00%
Last trade - 00:00- SEK175.25m
- -SEK116.71m
- SEK97.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.65% | ||
| Return on Equity | -33.26% | ||
| Operating Margin | -110.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.09 | 0.04 | n/a | n/a | 97.5 | n/a | 168 | 277.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Directors
- Wenche Rolfsen NEC (69)
- Peter Zerhouni CEO (44)
- Johan Gileus CFO (56)
- Pernilla Sandwall COO (57)
- Thomas Knittel OTH (54)
- Marlene Forsell IND (45)
- Uli Hacksell IND (71)
- Lennart Hansson IND (63)
- Stig Loekke Pedersen IND (60)
- Yilmaz Mahshid IND (42)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 27th, 2016
- Public Since
- October 11th, 2016
- No. of Employees
- 7
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 532,687,650
- Address
- Berzelius Vag 13, SOLNA, 171 65
- Web
- https://www.indexpharma.com/
- Phone
- +46 812203850
- Contact
- Johan Gileus
- Auditors
- PricewaterhouseCoopers AB
Upcoming Events for INDEX
InDex Pharmaceuticals Holding AB Annual Shareholders Meeting
InDex Pharmaceuticals Holding AB Annual Shareholders Meeting
Q2 2024 InDex Pharmaceuticals Holding AB Earnings Release
Similar to INDEX
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the InDex Pharmaceuticals Holding AB share price?
As of Today at 19:11 UTC, shares in InDex Pharmaceuticals Holding AB are trading at SEK0.33. This share price information is delayed by 15 minutes.
How has the InDex Pharmaceuticals Holding AB share price performed this year?
Shares in InDex Pharmaceuticals Holding AB last closed at SEK0.33 and the price had moved by -19.56% over the past 365 days. In terms of relative price strength the InDex Pharmaceuticals Holding AB share price has underperformed the FTSE Global All Cap Index by -24.48% over the past year.
What are the analyst and broker recommendations for InDex Pharmaceuticals Holding AB?
The overall consensus recommendation for InDex Pharmaceuticals Holding AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the InDex Pharmaceuticals Holding AB dividend yield?
InDex Pharmaceuticals Holding AB does not currently pay a dividend.
Does InDex Pharmaceuticals Holding AB pay a dividend?
InDex Pharmaceuticals Holding AB does not currently pay a dividend.
When does InDex Pharmaceuticals Holding AB next pay dividends?
InDex Pharmaceuticals Holding AB does not currently pay a dividend.
How do I buy InDex Pharmaceuticals Holding AB shares?
To buy shares in InDex Pharmaceuticals Holding AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of InDex Pharmaceuticals Holding AB?
As of the previous close price of SEK0.33, shares in InDex Pharmaceuticals Holding AB had a market capitalisation of SEK175.25m.
Where are InDex Pharmaceuticals Holding AB shares listed?
Here are the trading details for InDex Pharmaceuticals Holding AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: INDEX
What kind of share is InDex Pharmaceuticals Holding AB?
Based on an overall assessment of its quality, value and momentum InDex Pharmaceuticals Holding AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a InDex Pharmaceuticals Holding AB share price forecast for 2024?
The analyst consensus target price for shares in InDex Pharmaceuticals Holding AB is SEK0.27. That is 17.93% below the last closing price of SEK0.33.
Analysts covering InDex Pharmaceuticals Holding AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.49 for the next financial year.
What is the trend in the InDex Pharmaceuticals Holding AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InDex Pharmaceuticals Holding AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -62.44%.
As of the last closing price of SEK0.33, shares in InDex Pharmaceuticals Holding AB were trading -33.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the InDex Pharmaceuticals Holding AB PE Ratio?
The InDex Pharmaceuticals Holding AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of InDex Pharmaceuticals Holding AB?
InDex Pharmaceuticals Holding AB's management team is headed by:
- Wenche Rolfsen - NEC
- Peter Zerhouni - CEO
- Johan Gileus - CFO
- Pernilla Sandwall - COO
- Thomas Knittel - OTH
- Marlene Forsell - IND
- Uli Hacksell - IND
- Lennart Hansson - IND
- Stig Loekke Pedersen - IND
- Yilmaz Mahshid - IND